Related Experiment Video
Updated: Sep 20, 2026
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies
Rosetta Martiniello-Wilks1, Allison Dane, Elin Mortensen
1Oncology Research Centre, Prince of Wales Hospital Clinical School of Medicine, Faculty of Medicine, University of New South Wales, Level 2, Clinical Sciences Building, Barker Street, Randwick, NSW, 2031, Australia. r.martiniello@unsw.edu.au
Background:
The suitability of (C57BL/6 TRAMP x C57BL/6)F1 transgenic (TRAMP+) mice with well- to moderately-differentiated prostate cancer (PCa) was assessed for pre-clinical therapeutic studies.
Materials And Methods:
TRAMP+ and TRAMP- mice were assessed for variability in genitourinary tract weight, seminal vesicle weight, prostate weight/volume and histopathology. Time-points included the reported ages of average tumour onset (approximately 25 weeks) and PCa-induced death (approximately 33 weeks).
Results:
Seventy % of TRAMP+ mice aged 25-33 weeks had well- to moderately-differentiated PCa. At 25-28 weeks, the mean genitourinary tract weight was 2X greater and the mean prostate weight/volume was 1.5X more in TRAMP+ than in TRAMP- mice, respectively. Prostate weight/volume showed significant increases (p < 0.0001) by 2X and 3X, respectively by 31-33 weeks of age.
Conclusion:
The window for using the TRAMP model successfully for pre-clinical experimentation is 25-33 weeks provided that mice with poorly-differentiated PCa showing a large tumour burden are excluded.
